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Tumor necrosis factor-like weak inducer of apoptosis
(TWEAK) is known to have pivotal roles in various
inflammatory processes. The TWEAK receptor, fibroblast
growth factor-inducible 14 (Fn14), has various unique
functions under physiological and pathological conditions;
however, the therapeutic potential of its direct targeting
remains unknown. Here, we found that Fn14 expression
was highly upregulated in ischemic renal tissues and tubular
epithelial cells of patient biopsies and experimental animal
models of renal injury. To clarify the function of Fn14 in
ischemia reperfusion injury, we coincubated renal tubular
cells with ITEM-2, an anti-Fn14 blocking monoclonal
antibody, and found that it inhibited the production of
proinflammatory cytokines and chemokines after injury.
Furthermore, Fn14 blockade downregulated the local
expression of several proinflammatory mediators, reduced
accumulation of neutrophils and macrophages in ischemic
tissues, and inhibited tubular cell apoptosis. Importantly,
Fn14 blockade attenuated the development of chronic
fibrosis after ischemia reperfusion injury and significantly
prolonged the survival of lethally injured mice. Thus, we
conclude that Fn14 is a critical mediator in the pathogenesis
of ischemia reperfusion injury.
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Chronic kidney disease is currently a serious social medical
problem, and the number of patients is increasing year by
year worldwide.1–3 Chronic kidney disease is progressive and
finally reaches end stage that requires renal replacement
therapy. Renal transplantation may be curative and desirable
therapy for end-stage renal disease at present.4–6 Favorable
outcomes of renal transplantation have been increasing the
need for kidney grafts. To correct the imbalance between
available organs and the number of patients waiting for
grafts, the use of marginal organs that would usually be
discarded or expected to lead to malfunction after trans-
plantation may be required. Ischemia reperfusion injury
(IRI) is a critical barrier to use of these marginal organs and
thus needs to be overcome.
The underlying mechanisms of renal IRI are considerably
complex and multiple factors are involved. The initial phase
is associated with the generation of nontoxic oxygen species,
secretion of inflammatory cytokines and chemokines, and
increased activity of adhesion molecules that are important
initiators of the innate immune response. Those responses
lead to the activation and accumulation of neutrophils and
monocytes/macrophages, as well as endothelial activation,
thereby resulting in primary tissue damage.7,8 The inflam-
matory response induced by innate mechanisms in the early
phase of renal IRI is remarkably amplified by the subsequent
adaptive response.9,10 Furthermore, it is known that renal IRI
initiates and promotes the alloimmune response and has a
negative impact on long-term graft and patient survival.11,12
Therefore, renal IRI remains a critical clinical problem.
Tumor necrosis factor (TNF)-like weak inducer of
apoptosis (TWEAK) is a member of the TNF superfamily
that was originally identified in 1997 and suggested to have
pivotal roles in various inflammatory conditions because of
its proinflammatory property.13,14 In addition, fibroblast
growth factor-inducible 14 (Fn14) was discovered in 2001 as
a TWEAK receptor that is linked to several intracel-
lular signaling pathways, including the nuclear factor-kB
pathway.13,15,16 Several basic studies have shown that
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TWEAK–Fn14 interaction promotes cell proliferation, mi-
gration, differentiation, apoptosis, angiogenesis, as well as
inflammation in various cell types.17–20 Furthermore, recent
studies have gradually revealed that this pathway also has
important roles in a variety of disease conditions including
rheumatoid arthritis,21,22 multiple sclerosis,23 and systemic
lupus erythematosus.24 In addition, it has been suggested
that TWEAK/Fn14 pathway is acting as a neurotoxic factor
in the ischemic brain.25–28 Some of them have also suggested
a therapeutic potential of targeting TWEAK. However, the
clinical relevance of direct targeting of TWEAK receptor,
Fn14, in various disease conditions has not been evaluated. In
renal disorders, some studies have shown that TWEAK
mediates acute renal injury by increasing local immune
activation.29–31 Moreover, it has been recently reported that
soluble TWEAK plasma levels correlate with clinical outcome
in chronic kidney disease patients.32 Although those studies
have suggested that TWEAK/Fn14 pathway may be function-
ally important in both physiological and pathological
conditions in the kidney, relatively little is known about the
precise role of Fn14 in the renal injury. In this study, we
investigated the clinical significance and therapeutic potential
of targeting Fn14 in renal IRI. To this end, we employed
human kidney ischemic tissues as well as experimental renal
ischemic models. Toward clinical application, we further
evaluated immediate and long-term effect of Fn14 blockade
on renal IRI.
RESULTS
Fn14 protein is expressed in human ischemic kidney
First, we examined the Fn14 protein expression in human
ischemic kidney by immunohistochemistry. We used graft
biopsy specimens obtained 1-h after renal transplantation as
ischemic kidney samples. As a control, we used nonpatho-
logical kidney tissues obtained from nephrectomized surgical
specimen. Fn14 expression was not observed in control
human kidney tissues. In contrast, it was clearly expressed in
ischemic tubular cells (Figure 1). Data suggested that Fn14
was upregulated and might have some roles in the process of
renal IRI. To clarify the significance of Fn14 expression in IRI,
we used in vitro and in vivo models of renal IRI for the
following studies.
Fn14 expression is upregulated in the kidney after ischemia
We then evaluated Fn14 and TWEAK expression in an
in vitro renal IRI model. Primary human proximal tubular
epithelial cells (RPTECs) were immersed in mineral oil for
15 min. The cells were incubated for 1 h and then collected
for analysis. As a result, hypoxia stimulation induced a
significant upregulation of Fn14 expression in proximal
tubular epithelial cells. In contrast, RPTECs subjected to
hypoxia in vitro expressed similar levels of mRNA for
TWEAK compared with naı¨ve cells (Figure 2a). Next, to
determine whether renal ischemia stimulates Fn14 and
TWEAK upregulation in vivo, we measured mRNA expres-
sion of both molecules in the injured kidney using a murine
renal IRI model. The kidneys were collected at different time
points after reperfusion following 30 min of ischemia. Both
Fn14 and TWEAK mRNA levels were significantly increased
after reperfusion. However, although there was only 1.7-fold
increase in TWEAK expression in the kidney at 24 h after
reperfusion compared with controls, Fn14 expression was
highly upregulated, with peak induction at 6 h (16.4-fold
increase greater than control) (Figure 2b). Furthermore, we
examined the protein expressions of Fn14 and TWEAK in the
ischemic kidney at 24 h after reperfusion. Fn14 expres-
sion was observed in the cellular membrane of ischemic
tubular cells, but not in naı¨ve cells. Furthermore, Fn14 was
seen predominantly on the apical membrane and not on
the basolateral membrane in the ischemic tubular cells
(Figure 3a and b). In addition, Fn14 expression was localized
mostly to the corticomedullary junction of ischemic kidney
(Figure 3c). On the other hand, TWEAK protein was seen in
the cytoplasm of both naı¨ve and ischemic tubular cells
(Figure 3d and e). Its expression was diffusely distributed in
both naı¨ve and ischemic kidney (Figure 3f). Moreover, to
determine more precisely the localization of each molecule,
we separately extracted cytoplasmic, membrane, and nuclear
soluble proteins from the naı¨ve and ischemic kidney, and
then analyzed. Western blotting analysis clearly demonstrated
that Fn14 was expressed in the cellular membrane and the
nucleus, but not in the cytoplasm, of the ischemic kidney. In
sharp contrast, TWEAK expression was observed in the
cytoplasm of both naı¨ve and ischemic kidney, but not in
cellular membrane or nucleus (Figure 3g). Thus, Fn14
and TWEAK were not colocalized in the ischemic kidney
and the expression pattern during IRI was considerably
different. Taken together, Fn14 might function indepen-
dently of TWEAK and have more critical roles in the process
of renal IRI.
Fn14 blockade inhibits proinflammatory cytokine and
chemokine secretion from tubular cells in vitro
Next, we examined whether Fn14 blockade could prevent IRI
in vitro. We added an anti-Fn14 blocking monoclonal
antibody (mAb), ITEM-2, to RPTEC incubation medium
a b
Figure 1 | Fibroblast growth factor-inducible 14 (Fn14) protein
expression in human ischemic kidney. Immunostaining
demonstrated that Fn14 protein expression was absent in normal
tubular cells. In contrast, it was clearly identified in the membrane
of ischemic tubular cells. Representative sections of kidneys
from (a) normal kidney, (b) ischemic kidney. Magnification  400.
n¼ 7 per group.
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for 1 h after 15 min of hypoxia. This transient hypoxia did
not induce apoptosis on RPTEC. Then, we measured
cytokines on collected cells by quantitative real-time PCR.
Hypoxia-stimulated RPTECs expressed significantly higher
levels of cytokines including TNF-a, interleukin-1b, and
monocyte chemotactic protein-1, as compared with naı¨ve
cells. Coincubation with anti-Fn14 mAb significantly in-
hibited these expressions (Figure 4). Data suggested that
Fn14 might have a pivotal role to promote the ischemic
injury on proximal tubular epithelial cells.
Fn14 blockade prevents renal IRI in vivo
Next, to clarify the precise function of Fn14 in renal IRI
in vivo, we treated mice with ITEM-2 at 1 h before ischemia.
Mice were killed at 24 h after reperfusion, following 30 min of
ischemia. Fn14 blockade significantly prevented renal IRI, as
demonstrated by reduced serum creatinine and blood urea
nitrogen levels compared with controls. Serum creatinine and
blood urea nitrogen levels were 0.28±0.12 and 73.5±51.1,
respectively, in treated mice. They were 0.54±0.24 and
126.0±54.4 in controls (Figure 5a and b). This protective
effect of mAb treatment on IRI was also confirmed by
histological analysis. Severe tubular necrosis and massive
cellular infiltrations were identified at corticomedullary
junction in the injured kidney compared with sham-operated
control (Figure 5c and d). In contrast, there were less necrosis
and cellular infiltrations in the kidneys treated by anti-Fn14
mAb (Figure 5e). Furthermore, semiquantitave analysis of the
histological change scored by the percentage of tubular
necrosis indicated that the treatment significantly reduced
tubular damage (Figure 5f). Taken together, Fn14 activation
may have important roles to promote renal IRI in vivo and its
blockade may have a therapeutic potential.
Fn14 blockade suppresses local immune activation and
interstitial cellular infiltration
To elucidate the underlying mechanisms for the protective
effect of Fn14 blockade on renal IRI, we examined the local
expressions of proinflammatory cytokines, chemokines, and
adhesion molecules in the kidney after reperfusion by
quantitative real-time PCR analysis. Anti-Fn14 mAb treat-
ment significantly downregulated the expression of several
proinflammatory cytokines including TNF-a and interleu-
kin-1b compared with controls (Figure 6a). In addition, the
treatment also inhibited several chemokines such as mono-
cyte chemotactic protein-1 and macrophage inflammatory
proteins-2 (Figure 6b). Furthermore, some adhesion mole-
cules including intercellular adhesion molecule 1 and
E-selectin were also significantly downregulated by Fn14
blockade (Figure 6c). Thus, the protective effect of Fn14
blockade on renal IRI might be associated with the inhibition
of local immune activation. As it is widely recognized that
neutrophils have a critical role in IRI, we directly examined
the neutrophil accumulation in the ischemic kidney
using myeloperoxidase staining. A considerable number of
neutrophils were identified in control kidneys at 24 h
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Figure 2 | Fibroblast growth factor-inducible 14 (Fn14) and tumor necrosis factor-like weak inducer of apoptosis (TWEAK) mRNA
expression in naive and ischemic kidney. (a) Primary human proximal tubule epithelial cells (RPTECs) subjected to hypoxia expressed
significantly higher levels of mRNA for Fn14 than naive cells. In contrast, there was no difference in TWEAK expression between the two
groups. *Po0.05 versus naive control. Results are expressed as the mean±s.d. (n¼ 4). (b) The serial change of Fn14 and TWEAK mRNA
expression in the process of renal ischemia reperfusion injury (IRI) in mice, as determined by real-time PCR. Fn14 mRNA levels were greatly
increased, with peak induction at 6 h after reperfusion. In TWEAK expression, there was only a 1.7-fold increase in the kidney at 24 h after
reperfusion compared with controls. Data were normalized to the levels of b2-microglobulin. Results are expressed as the mean±s.d.
(n¼ 4). The comparison between IRI kidney and sham-operated control is indicated by asterisks. *Po0.05, **Po0.001 versus sham-operated
controls.
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after reperfusion compared with sham-operated kidney
(Figure 7a and b). In contrast, comparatively few neutrophils
were observed in the kidneys treated with anti-Fn14 mAb
(Figure 7c). By quantitative analysis, we found a significant
reduction of accumulated neutrophils in the treated kidneys
compared with controls (Figure 7d). We also examined the
macrophage accumulation by F4/80 staining. Interstitial
macrophages progressively accumulated in control kidneys
at 24 h after reperfusion (Figure 7e and f). Relatively less
interstitial macrophages were identified in treated kidneys
(Figure 7g). The difference was also statistically significant
(Figure 7h).
Fn14 blockade reduces apoptosis induced by IRI
Next, we evaluated the apoptosis of renal cells caused by IRI
using terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay. In control kidneys, apoptotic cells
were abundant at 24 h after IRI. Those cells were identified
mainly at the corticomedullary junction (Figure 8a and b). In
contrast, there were less apoptotic cells observed in the
kidneys treated by Fn14 blockade (Figure 8c). The number of
apoptotic cells in controls was significantly higher than in the
kidneys treated with ant-Fn14 mAb (Figure 8d). Thus, Fn14
blockade had a significant favorable impact on IRI-induced
apoptosis.
Fn14 blockade attenuates chronic fibrosis induced by IRI
Furthermore, we evaluated long-term effect of Fn14 blockade
on renal IRI. To this end, we stained the kidneys at 30 days
after reperfusion with Masson trichrome staining to assess
the deposition of collagen as an indicator of fibrosis. In
control kidneys, there was a clear decrease in the renal
tubules, and renal interstitial tissue was replaced by collagen
deposition compared with sham-operated kidney (Figure 9a
and b). In contrast, kidney tubular architecture was
moderately preserved and there was less collagen deposition
seen in the kidneys treated by anti-Fn14 mAb (Figure 9c).
Quantitative analysis by calculating the percentage of
collagen deposition indicated that Fn14 blockade signifi-
cantly attenuated the development of chronic tubular fibrosis
(Figure 9d).
Fn14 blockade improves survival in lethally injured mice
Finally, to confirm the therapeutic efficacy of Fn14 blockade
on renal IRI, we used a lethal renal IRI model. The left
kidney vessels of mice were clamped for 40 min after right
nephrectomy. Anti-Fn14 mAb was administered 1 h before
ischemia. The survival rates at 7 days after reperfusion in
control and anti-Fn14 mAb-treated mice were 9 and 50%,
respectively. The survival rate in treated mice was signifi-
cantly higher than that in controls (Figure 10). The data
clearly demonstrated that Fn14 blockade had a thera-
peutic efficacy and significantly improved survival after
severe renal IRI.
DISCUSSION
Accumulating evidence has indicated that TWEAK is a
multifunctional cytokine and has a key unique role in a
variety of physiological and pathological conditions. TWEAK
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Figure 3 | Localization of fibroblast growth factor-inducible
14 (Fn14) and tumor necrosis factor-like weak inducer of
apoptosis (TWEAK) protein expression in naive and ischemic
kidney. Immunostaining demonstrated that Fn14 protein was
expressed in cellular membrane of ischemic tubular cells at 24 h
after reperfusion, but not in naive cells in mice. Representative
sections from (a) naive and (b) ischemic kidney. Magnification,
 1000. (c) Fn14 expression was localized mostly to the
corticomedullary junction of ischemic kidney at 24 h after
reperfusion. Arrowheads indicate CMJ. Magnification,  40. C,
cortex; CMJ, corticomedullary junction; M, medulla. TWEAK
protein expression was observed in cytoplasm of both naive and
ischemic tubular cells at 24 h after reperfusion. Representative
sections from (d) naive and (e) ischemic kidney. Magnification,
 1000. (f) TWEAK expression was diffusely distributed in ischemic
kidney at 24h after reperfusion. Magnification,  40. C, cortex; CMJ,
corticomedullary junction; M, medulla. (g) Western blotting analysis
revealed that Fn14 expression was increased in cellular membrane
and nucleus, but not in cytoplasm, following ischemia reperfusion.
In sharp contrast, TWEAK expression was identified in the cytoplasm
of both naive and ischemic kidney at about the same level.
E-cadherin, actin, and lamin A were used as markers of cellular
membrane, cytoplasm, and nucleus. IR, ischemia reperfusion;
N, naive.
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is widely expressed in various cells and organs.14 It is
produced by many immune cells including monocytes/
macrophages, dendritic cells, natural killer cells, as well
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Figure 4 |Cytokines gene expression in hypoxia-stimulated human tubular epithelial cells. RPTECs were rendered transiently
ischemic by immersing the cellular monolayer in mineral oil for 15min. After washing with phosphate-buffered saline, cells were
incubated in medium for 1 h and collected for real-time PCR analysis. Hypoxia-stimulated RPTECs expressed significantly higher
tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b), and monocyte chemotactic protein-1 (MCP-1), as compared with naive cells.
Fibroblast growth factor-inducible 14 (Fn14) blockade significantly inhibited these gene expressions. Data were normalized to the
levels of b2-microglobulin. Results are expressed as the mean±s.d. (n¼ 4). *Po0.05 versus hypoxia; **Po0.01 versus hypoxia;
***Po0.001 versus naive.
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Figure 5 | Fibroblast growth factor-inducible 14 (Fn14)
blockade significantly inhibits tubular injury induced by renal
ischemia reperfusion injury (IRI). (a) Serum creatinine and (b)
blood urea nitrogen (BUN) levels after renal IRI. Mice were killed at
24 h after reperfusion following 30min of ischemia (IR). Fn14
blockade inhibited renal IRI with significantly lower serum
creatinine and BUN compared with controls at 24 h after
reperfusion. *Po0.05, **Po0.01 versus control immunoglobulin
(Ig)-treated mice. Data expressed as mean±s.d. (n¼ 10).
Representative sections of corticomedullary junction from
(c) sham-operated, (d) control Ig-treated, and (e) anti-Fn14
monoclonal antibody (mAb)-treated mice at 24 h after reperfusion
(hematoxylin and eosin staining). Magnification,  200.
(f) Quantitative analysis of tubular damage in sham-operated,
control, and anti-Fn14 mAb-treated kidneys at 24 h after
reperfusion. Results are expressed as the mean±s.d. n¼ 6 per
group. ***Po0.001 versus control Ig-treated mice.
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Figure 6 | Fibroblast growth factor-inducible 14 (Fn14)
blockade significantly inhibits local immune activation. Mice
were killed at 24 h after reperfusion following 30min of ischemia
(IR). The mRNA expression of proinflammatory cytokines,
chemokines, and adhesion molecules in the kidney were
determined by real-time PCR. Fn14 blockade significantly
inhibited the local expression of (a) tumor necrosis factor-a
(TNF-a) and interleukin-1b (IL-1b), (b) monocyte chemotactic
protein-1 (MCP-1) and macrophage inflammatory proteins-2
(MIP-2), and (c) intercellular adhesion molecule 1 (ICAM-1)
and E-selectin at 24 h after reperfusion. Data were normalized to
the levels of b2-microglobulin. Results are expressed as the
mean±s.d. (n¼ 6). *Po0.05; **Po0.01; ***Po0.001 versus
control immunoglobulin-treated mice.
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as activated T cells.33–36 TWEAK mediates its biological
activities through specific binding to its only known receptor,
Fn14. Although a few reports have suggested that TWEAK
might bind to unknown receptor, those putative receptors
and functions have not yet been clarified.19,37 Furthermore,
although Fn14 is expressed in normal and healthy tissues at
relatively low level, it can be upregulated or induced after
various tissue injuries and during tissue repair.15,25,27,38,39 In
renal tissues, both TWEAK and Fn14 is upregulated in
experimental murine acute inflammation induced by folic
acid.29,30 More recently, it has been shown that Fn14 is
expressed on cultured human kidney cells including mesan-
gial cells, podocytes, and tubular cells.31 In this study, we also
confirmed that ischemic stimulation induces a significant
upregulation of Fn14 in human proximal tubular epithelial
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Figure 7 | Fibroblast growth factor-inducible 14 (Fn14)
blockade reduces the neutrophil and macrophage infiltration
into the ischemic kidney. The neutrophil accumulation in the
kidney was examined using myeloperoxidase staining at 24 h after
reperfusion following 30min of ischemia (IR). Representative
sections of kidneys from (a) sham-operated, (b) control
immunoglobulin (Ig)-treated, and (c) anti-Fn14 monoclonal
antibody (mAb)-treated mice. Magnification,  200.
(d) Quantitative analysis of neutrophil infiltrates. Results are
expressed as the mean±s.d. (n¼ 6). **Po0.001 versus control
Ig-treated mice. The macrophage accumulation in the kidney was
examined using F4/80 staining at 24 h after reperfusion following
30min of ischemia. Representative sections of kidneys from
(e) sham-operated, (f) control Ig-treated, and (g) anti-Fn14
mAb-treated mice. Magnification,  200. (h) Quantitative
analysis of macrophage infiltrates. Results are expressed as the
mean±s.d. (n¼ 6). *Po0.01 versus control Ig-treated mice; HPF,
high-power field.
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Figure 8 | Fibroblast growth factor-inducible 14 (Fn14)
blockade inhibits apoptosis of renal cells induced by ischemia
reperfusion injury (IRI). The apoptotic cells were evaluated by
terminal deoxynucleotidyl transferase dUTP nick end labeling
staining at 24 h after reperfusion following 30min of ischemia (IR).
Representative sections of kidneys from (a) sham-operated,
(b) control immunoglobulin (Ig)-treated, and (c) anti-Fn14
monoclonal antibody-treated mice. Magnification,  200.
(d) Quantitative analysis of apoptotic cells. Results are expressed
as the mean±s.d. (n¼ 6). *Po0.001 versus control Ig-treated
mice. HPF, high-power field.
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Figure 9 | Long-term effect of fibroblast growth factor-
inducible 14 (Fn14) blockade on chronic fibrosis induced by
renal ischemia reperfusion injury (IRI). The deposition of
collagen as an indicator of fibrosis was evaluated by Masson
trichrome staining at 30 days after reperfusion. Representative
sections of kidneys from (a) sham-operated, (b) control
immunoglobulin (Ig)-treated, and (c) anti-Fn14 monoclonal
antibody-treated mice. Magnification,  200. (d) Quantitative
analysis of fibrosis. Results are expressed as the mean±s.d. (n¼ 6).
*Po0.01 versus control Ig-treated mice. IR, ischemia reperfusion.
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cells. However, there is little known about its expression in
clinical settings. In this study, we first examined the protein
expression of Fn14 in the human kidney under ischemic
conditions. Inconsistent with a previous report on cultured
human cells, Fn14 was not expressed in normal human
kidney under physiological condition.31 Furthermore, Fn14
expression was clearly identified in the ischemic tubular cells
at 1 h after renal transplantation. However, it was not
expressed on mesangial cells and podocytes in our analysis
on clinical materials. Ischemic stimuli have been shown to
induce both TWEAK and Fn14 expression in stroke in
animals and humans.25–28 There was 16.4-fold increase in
Fn14 expression compared with controls in our in vivo
model, whereas TWEAK expression was increased by only
1.7-fold. Similar results have been previously reported in a
mouse stroke model in which 22-fold upregulation of Fn14
and only twofold increase of TWEAK were observed.25
Moreover, Fn14 and TWEAK proteins were not colocalized in
the ischemic kidney. These results suggest that ischemia
stimulation may have a differential effect on induction of
each molecule in injured tissues. Furthermore, direct
targeting of TWEAK receptor may have a substantial
therapeutic efficacy through TWEAK-dependent and
-independent mechanisms. In fact, several studies have
reported that TWEAK-independent Fn14 signaling can occur
and may be enough for various responses including cell
migration and invasion.40,41 Furthermore, previous studies
have reported that several growth factors, cytokines,
hormones, and compounds could increase Fn14 expression
in several cell types.36,38,42,43 In murine tubular epithelial
cells, Fn14 was upregulated by TNF-a and IFN-g stimula-
tion.29 Taken together, Fn14 may be critically important in
the process of human renal IRI and may also have
considerable therapeutic potential.
To test our hypothesis, we evaluated a strategy targeting
Fn14 to prevent renal IRI. As demonstrated by several in vitro
and in vivo data, we found a substantial efficacy of anti-Fn14-
blocking mAb. Although TWEAK blockade has been shown
to prevent murine acute renal inflammation,30 we are the
first to demonstrate direct effect of Fn14 blockade.
The underlying mechanisms may be complex, as Fn14 have
a variety of biological activities. First, TWEAK/Fn14 pathway
is well known to have a proinflammatory property and be
involved in various inflammatory conditions. Therefore,
antiinflammatory function of Fn14 blockade is likely a key
mechanism regulating renal IRI. This was strongly sup-
ported by our in vitro and in vivo data. Downregulation
of proinflammatory cytokines, chemokines, and adhesion
molecules by Fn14 blockade could also result in suppression
of the secondary response including activation and accumu-
lation of various inflammatory cells in ischemic tissues.
Second, it is possible that Fn14 blockade directly inhibits the
infiltrations of Fn14-expressing inflammatory cells, including
monocytes/macrophages and neutrophils, into the ischemic
tissues. However, immunohistochemical analysis did not
clearly indicate the Fn14 expression on infiltrating cells in our
model. Third, although TWEAK and Fn14 have been shown
to regulate positively and negatively the apoptotic pathway
under various circumstances depending on the cell type and
physiological context,14,39,44–48 it has been shown that a
neutralizing anti-Fn14 antibody (Ab) prevented TWEAK-
induced cell death on cultured renal tubular cells costimu-
lated with TNF-a/IFN-g.29 Therefore, it is possible that Fn14
blockade could inhibit apoptosis of ischemic tubular cells
under an in vivo physiological condition. This was corrobo-
rated by our data determined by TUNEL assay. Taken
together, Fn14 blockade may probably exhibit its substantial
therapeutic effect on renal IRI through these apoptosis-
dependent and -independent mechanisms that are not
mutually exclusive.
Far from the originally proposed biology of TWEAK/Fn14
pathway, several studies have suggested its unique function as
a critical regulator in tissue regeneration and remodeling.
First, it has been shown that Fn14 could be induced in the
process of different tissue regeneration and repair after
surgical and chemical stimulation.38,39,48,49 Second, Fn14 has
been identified in various progenitor cells existing in many
kinds of tissues.39,48 Third, the regenerative and proliferative
capacities of Fn14 would be impaired in gene-deficient mice
or in blocking Ab-treated mice.39,48 Thus, it is likely that
Fn14 universally regulates a variety of tissue regeneration and
repair under physiological and pathological conditions.
Therefore, before clinical application of targeting Fn14 in
humans, its long-term effect of Fn14 blockade on tissue
repair should be taken into consideration. Renal tissue repair
is presumably a physiological process after IRI. Therefore, if
TWEAK/Fn14 is involved in tubular regeneration after renal
IRI, Fn14 blockade may have detrimental effects on tissue
repair. To examine whether Fn14 blockade lead to inhibition
of tubular regeneration after IRI, we evaluated chronic
tubular change by staining collagen deposition as an
indicator of fibrosis. Then, we found a clear decrease in
collagen deposition observed in anti-Fn14 mAb-treated
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Figure 10 | Fibroblast growth factor-inducible 14 (Fn14)
blockade prolongs mouse survival after severe renal ischemia
reperfusion injury (IRI). The left kidney vessels of mice were
clamped for 40min following right nephrectomy. Anti-Fn14
monoclonal antibody (mAb) was administered 1 h before
ischemia. The survival rates at 7 days after reperfusion in control
immunoglobulin-treated (n¼ 10) and anti-Fn14 mAb-treated mice
(n¼ 11) were 9 and 50%, respectively. The difference in survival
between two groups was statistically significant (Po0.05).
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kidneys compared with controls. Thus, Fn14 blockade could
also inhibit the development of chronic tubular damage after
IRI and would not interfere with renal tissue repair.
In conclusion, our findings may have clinical relevance
and provide new insights into pathogenesis of renal IRI.
Importantly, this study provides strong evidence that Fn14
has a significant therapeutic potential as a novel target to
overcome renal IRI. Furthermore, targeting Fn14 may be of
clinical benefit in the treatment of other human disorders, as
the function of TWEAK/Fn14 pathway seems to be universal.
MATERIALS AND METHODS
Human kidneys
We used graft biopsy specimens obtained 1-h after renal transplan-
tation as ischemic kidney samples. As a control sample, normal
kidney was obtained from nephrectomized surgical specimen.
Anti-Fn14 mAb
Anti-human Fn14 mAb (ITEM-2) was prepared as described
previously.17,46 It was confirmed to cross-react with murine Fn14.50
Cell culture and induction of hypoxia in vitro
Primary human proximal tubule epithelial cells (RPTEC) were
obtained from Lonza (Walkersville, MD). RPTECs were rendered
transiently ischemic by immersing the cellular monolayer in mineral
oil, according to the protocol of Meldrum et al.51 This immersion
induced simulated ischemia by restricting cellular exposure to
oxygen and nutrients, as well as by limiting metabolite washout.
RPTECs were placed for 24 h and then washed twice with
phosphate-buffered saline before immersing in mineral oil for
15 min at 37 1C. After washing, the cells were incubated and
collected at 1 h after medium replacement. In some experiments, we
added ITEM-2 (50mg/ml) for 1 h after 15 min of hypoxia.
Mice and induction of renal IRI in vivo
Male C57BL/6 mice, 8–10 weeks old, were obtained from CLEA
Japan (Tokyo, Japan). For the renal IRI, the right kidney was
removed and left renal pedicle was clamped with an atraumatic
arterial clamp for 30 min. Based on published literatures and our
own preliminary experiments, we determined the time and
temperature to keep mice during ischemia.52,53 Mice were placed
on thermoregulated pad to maintain body temperature at 32–33 1C.
Under our conditions, mice sometimes died after reperfusion
following ischemia with higher temperature. Sham-operated mice
received only right nephrectomy. In a lethal model, the left kidney
vessels were clamped for 40 min after right nephrectomy. In some
mice, 0.5 mg of ITEM-2 was intraperitoneally injected 1 h before
ischemia. Some mice received isotype immunoglobulin as control.
Assessment of kidney function
Blood samples were obtained by cardiac puncture, immediately
centrifuged at 3000 g for 10 min, and stored at 20 1C until analysis.
Serum creatinine and blood urea nitrogen were measured.
Histological examination
The removed kidneys were fixed in 10% formalin at 24 h after
reperfusion following 30 min of ischemia. The samples embedded in
paraffin were sectioned into 5-mm-thick sections for staining.
Markers of tubular damage were scored by calculation of percentage
of tubules in corticomedullary junction that displayed cell necrosis,
loss of brush border, cast formation, and tubular dilation as follows:
0, none; 1,p10%; 2, 11–25%; 3, 26–45%; 4, 46–75%; and 5, 476%.
At least five high-power fields (magnification,  200) per section
were examined.54 For analysis of chronic change after ischemia
reperfusion, we stained the kidneys at 30 days after reperfusion with
Masson’s trichrome staining. Fibrosis was scored by calculation of
percentage of tubules that displayed the deposition of collagen as
follows: 0, none; 1,p10%; 2, 11–25%; 3, 26–45%; 4, 46–75%; and 5,
476%. At least five high-power fields (magnification,  200) were
examined.
Immunohistochemistry
For immunohistochemistry, mice were reanesthetized after reperfu-
sion and killed. In some mice, the kidney was fixed in situ with 4%
paraformaldehyde by transcardiac perfusion, and then har-
vested.55,56 The sections were incubated for 30 min at 37 1C with
rabbit anti-human Fn14 Ab (Abcam, Tokyo, Japan), anti-mouse
Fn14 Ab (Cell Signaling Technology, Beverly, MA), anti-TWEAK Ab
(Anaspec, Fremont, CA), anti-myeloperoxidase Ab (Lab Vision,
Fremont, CA), and anti-F4/80 Ab (Santa Cruz Biotechnology, Santa
Cruz, CA), followed by incubation for 30 min at 37 1C with
EnVisionþ Rabbit-HRP (DAKO, Tokyo, Japan). Revealing reaction
was performed using 3,30-diaminobenzidine substrate–chromogen
solution.
Western blot analysis
Subcellular Protein Fraction Kit (Thermo Fisher Scientific,
Waltham, MA) was used to extract cellular membrane, cytoplasmic,
and nuclear soluble proteins from mouse kidney. The lysates were
resolved in 10% SDS polyacrylamide gels and then transferred to
polyvinylidene difluoride membranes (Millipore, Billerica, MA) that
were then blocked in 5% skimmed milk at room temperature
for 1 h. The membranes were incubated with ant-Fn14 Ab (Cell
Signaling Technology), anti-TWEAK Ab (Anaspec), anti-E-cadherin
Ab (Cell Signaling Technology), anti-actin Ab, and anti-lamin A Ab
(Santa Cruz Biotechnology). Then, these were incubated with
horseradish peroxidase-conjugated anti-rabbit IgG (Santa Cruz
Biotechnology) or anti-mouse IgG (Santa Cruz Biotechnology).
Peroxidase activity was detected on X-ray film using an enhanced
chemiluminescence detection system.
TUNEL assay
The kidneys were fixed in 10% buffered formalin, embedded in
paraffin, and cut into 5-mm-thick sections. The sections were
evaluated quantitatively for apoptotic nuclei by TUNEL assay with
ApopTag Plus Peroxidase In Situ Apoptosis Kit (Millipore/
Chemicom International) in accordance with the manufacturer’s
recommendations.
Quantification of the infiltrated and apoptotic cells
Analysis of the cellular infiltrate and apoptosis was performed in five
nonoverlapping fields of the corticomedullary junction on each
section at  200 magnification. Using an ocular grid, the number of
positively stained cells in each tissue was counted and expressed as
cells per high-power field.
Real-time reverse transcriptase PCR
Total RNA was isolated from kidney samples and tubule epithelial
cells using RNAspin Mini (GE Healthcare, Tokyo, Japan). cDNA was
186 Kidney International (2011) 79, 179–188
or ig ina l a r t i c l e K Hotta et al.: Fn14 blockade protects against renal IRI
synthesized from 1 mg RNA using a High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA) following a
standard protocol. Specific Taqman primers and probes were
obtained from Applied Biosystems. cDNA was amplified in TaqMan
Fast Universal PCR Master Mix with gene-specific primers
and probe on the StepOnePlus Real-Time PCR System. Expres-
sion of each gene was normalized against mRNA expression of the
housekeeping gene b2-microglobulin. Real-time PCR experiments
for each gene were performed on three independent experiments.
Statistical analysis
The mean and standard deviation were calculated for all parameters
determined in the study. Statistical significance between two groups
of parametric date was evaluated using an unpaired Student’s t-test.
P-values o0.05 were considered significant. The survival curve, as
determined with the Kaplan–Meier method, was analyzed using a
log-rank test.
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